Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure presenting the final voting results from Ascent Industries' Annual Meeting of Shareholders held June 10, 2026. The filing reports tabulated votes for three proposals: election of seven directors, advisory approval of named executive officer compensation, and ratification of Baker Tilly US, LLP as independent auditor. All results are presented in standard vote-count format (For, Against, Abstain, Broker Non-Votes), which is the hallmark of shareholder_vote_results classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-10
Item 5.07
The filing discloses results of a shareholder vote at the Annual Meeting of Shareholders on June 10, 2026, where the Board of Directors was re-elected in its entirety. This is a classic shareholder_vote_results disclosure under Item 5.07, and board re-election is material to investors as it affects corporate governance and oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear disclosure of shareholder vote results from Valaris Limited's 2026 Annual General Meeting held on June 10, 2026. The filing reports voting outcomes on three matters: election of six directors (Elizabeth D. Leykum, Anton Dibowitz, Dick Fagerstal, Joseph Goldschmid, Catherine J. Hughes, and Kristian Johansen), advisory approval of named executive officer compensation, and appointment of KPMG LLP as independent auditor. This is a quintessential Item 5.07 disclosure with detailed vote tallies (For, Against, Abstain, Non-Votes) for each proposal.
View raw filing on EDGAR →
8-K
M&A activity
confidence 72%
filed 2026-06-10
Item 1.01
Werner Enterprises entered into Amendment No. 3 to its Loan and Security Agreement on June 5, 2026, increasing the maximum funding limit from $325 million to $350 million with potential increase to $400 million, and adding a Performance Guaranty by the parent company. This material amendment to the company's credit facility affects its capital structure and liquidity.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-10
Item 7.01
The filing discloses preliminary assets under management (AUM) as of May 31, 2026 via a news release furnished under Regulation FD Disclosure. While AUM is a key operational metric for asset managers that investors monitor, this disclosure does not fit cleanly into the standard event taxonomy (not earnings, M&A, executive changes, impairments, etc.). The materiality depends on whether the AUM figures represent significant changes, but the disclosure itself—a routine monthly/quarterly AUM announcement—is a standard practice for asset managers and may be administrative rather than material in the strict sense.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-10
Item 5.02
Colin M. Adams was elected as a director of Sleep Number's Board effective immediately on June 4, 2026, increasing the Board to 7 members with 6 independent directors. This is a clear executive appointment event. While the disclosure also mentions his compensation arrangement ($40,000 monthly fee), the principal action disclosed is the appointment itself, not a compensation arrangement modification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from FCX's 2026 annual meeting held on June 10, 2026. The filing reports final voting tallies for three proposals: election of eleven directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with substantial majorities, and the disclosure includes detailed vote counts (for, against, abstentions, and broker non-votes) for each director nominee and proposal, which is the standard format for shareholder meeting results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from Credit Acceptance's June 10, 2026 Annual Meeting of Shareholders. The filing reports voting outcomes on three proposals: election of six directors, advisory approval of named executive officer compensation, and ratification of Grant Thornton LLP as independent auditor. The detailed vote tallies (For, Against, Abstain, Broker Non Votes) for each proposal are the core content of the filing, making this unambiguously a shareholder_vote_results event that is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-06-10
Item 5.02
Joseph Billante was elected and appointed as Chief Financial Officer effective July 27, 2026, succeeding retiring CFO Jay D. Martin. The disclosure includes Billante's background and compensation package as part of the appointment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-10
Item 1.01
HNI entered into Amendment No. 3 to its Credit Agreement on June 10, 2026, providing a new $498.75 million tranche of term loans maturing in 2032 to refinance all outstanding Initial Tranche B Term Loans, representing a material modification to the company's capital structure and debt obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure reporting the final voting results from Biogen's June 9, 2026 Annual Meeting of Stockholders. The filing presents detailed vote tallies for three matters: election of ten directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of executive compensation. These are routine but material shareholder governance matters that affect investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-10
Item 5.02
The filing discloses the Board's appointment of Anthony Vang as the Company's full-time Chief Financial Officer effective June 5, 2026. Although Mr. Vang has performed CFO duties since inception, the formal appointment to the CFO title is the principal disclosed action. This is material as it represents a formal governance change and clarifies the CFO role structure ahead of the Company's Nasdaq uplisting application.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-10
Item 8.01
InMed received a Nasdaq notice on March 27, 2026 that its closing bid price fell below the $1.00 minimum requirement under Nasdaq Listing Rule 5550(a)(2), creating delisting risk. Although the Company subsequently regained compliance by June 3, 2026, the disclosure centers on the failure to satisfy a continued listing rule and the remediation thereof—the core substance of delisting_risk. This is material to investors as it directly affects the registrant's exchange listing status.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear disclosure of shareholder voting results from TeraWulf's June 9, 2026 Annual Meeting of Stockholders, covering three proposals: election of nine directors, advisory vote on executive compensation, and ratification of Deloitte as independent auditor. The filing presents detailed vote tallies for each proposal, which is the core content of Item 5.07 disclosures and is material to investors assessing corporate governance and board composition.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-06-10
Item 4.01
The filing discloses the dismissal of Bush & Associates CPA LLC as the Company's independent registered public accounting firm on June 10, 2026, and the appointment of DiPiazza LaRocca Heeter & Co., LLC as the new auditor effective for the fiscal year ending December 31, 2026. This is a classic auditor change under Item 4.01. While the prior auditor's reports contained a 'going concern' qualification, the primary disclosed event is the change in auditors itself, not the going concern matter (which is historical and already disclosed in prior filings).
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-06-10
Item 7.01
The filing discloses a press release providing a "performance update as of and for the period ended May 31, 2026," which constitutes a financial results disclosure. Although filed under Item 7.01 (Regulation FD Disclosure) rather than the more typical Item 2.02, the substance is an earnings release—a periodic financial performance update material to investors' assessment of the registrant's operating results and financial condition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-10
Item 7.01
This disclosure reports material regulatory approvals for the proposed merger between Paramount Skydance Corporation and Warner Bros. Discovery, Inc., including clearance from the Australian Competition and Consumer Commission (ACCC) and notifications from the New Zealand Commerce Commission (NZCC), along with approvals from multiple other competition and foreign direct investment authorities. The filing explicitly references the Agreement and Plan of Merger dated February 27, 2026, and describes the progression toward closing of this transformative transaction, making this a core M&A activity disclosure under Item 1.01/2.01 framework.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-10
Item 8.01
Celanese issued a notice of redemption for $4.777% Senior Notes due July 19, 2026, with redemption scheduled for June 25, 2026 at par plus accrued interest. While debt redemption is a routine capital management activity, the materiality depends on the principal amount outstanding (not disclosed here). The timing—redemption just before maturity—suggests refinancing or debt paydown activity that would be material to investors assessing the company's capital structure and liquidity, but the disclosure lacks sufficient detail to classify as a more specific event type.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-10
Item 8.01
Chubb INA Holdings agreed to sell C$800 million in senior notes (C$400M due 2031 at 3.780% and C$400M due 2033 at 4.034%), fully guaranteed by Chubb Limited. This is a material debt issuance that raises capital and increases financial obligations, but does not fit cleanly into the M&A, dilutive equity issuance, or other specific debt-related categories (covenant breach, going concern). The disclosure is material to investors assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →
8-K
Other material
confidence 35%
filed 2026-06-10
Item 1.01
Amazon entered into a material definitive agreement. The specific nature of the agreement—whether involving acquisition, disposition, merger, strategic partnership, or another material contract—cannot be determined from the limited disclosure provided.
View raw filing on EDGAR →
8-K
Other material
confidence 35%
filed 2026-06-10
Item 2.03
Amazon created a direct financial obligation or off-balance sheet arrangement. The specific nature of the obligation—whether debt issuance, lease arrangement, contingent liability, or other financial commitment—cannot be determined from the limited disclosure provided.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-06-10
Item 2.01
Masimo completed a merger in which shareholders received $180.00 per share in cash consideration, resulting in Masimo becoming a wholly owned subsidiary of the acquirer. The merger involved automatic cancellation and conversion of common stock and equity awards, modification of security holder rights, amendment of governing documents, termination of a material credit agreement, and delisting from Nasdaq.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-06-10
Item 5.02
Six directors (Catherine Szyman, Michelle Brennan, Quentin Koffey, Wendy Lane, Tim Scannell, and Darlene Solomon) resigned from the board, and three named executives (Catherine Szyman, Gregory Meehan, and Charles Dadswell) resigned from employment, all effective at the merger closing date.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Lulu's Fashion Lounge's Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting tallies for four proposals: election of two Class II directors (Anisa Kumar and Crystal Landsem), ratification of Deloitte & Touche LLP as auditor, approval of a certificate amendment reducing authorized shares, and approval of officer exculpation provisions. All proposals passed. Shareholder vote results are material to investors as they confirm governance outcomes and corporate actions approved by the shareholder base.
View raw filing on EDGAR →
8-K
Other material
confidence 50%
filed 2026-06-10
Item 1.01
B&G Foods closed a $475 million senior notes offering on June 10, 2026, and entered into a material definitive agreement related to the offering. The company intends to use proceeds to redeem $509.3 million of existing senior notes due 2027, effectively refinancing its debt structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-10
Item 5.07
Voyager's stockholders approved the 2026 Annual Meeting matters, including election of three Class II directors (Geraghty, Hyman, Sandrock), an advisory vote on named executive officer compensation, ratification of Ernst & Young LLP as independent auditor, and an amendment to increase authorized shares from 125 million to 245 million total shares and from 120 million to 240 million common shares.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear disclosure of shareholder vote results from Grand Canyon Education's 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes on four matters: election of six directors, approval of the 2026 Equity Incentive Plan, advisory approval of named executive officer compensation, and ratification of KPMG LLP as independent auditor. The detailed vote tallies (for, against, abstain, broker non-votes) for each proposal are the hallmark of Item 5.07 disclosures and constitute material information affecting investor understanding of corporate governance and shareholder sentiment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
Entrada Therapeutics held its Annual Meeting of stockholders on June 10, 2026, with shareholders voting on four proposals: election of two Class II directors (Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D.), ratification of Ernst & Young LLP as independent auditor, and approval of Amendment No. 1 to both the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan. All proposals passed with clear majorities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-10
Item 5.02
Mark A. Talley was appointed as an Independent Trustee to fill a vacancy on the Board, with assignment to three committees. Jeffrey P. Somers resigned from the Board, but the filing's principal focus is on Talley's election and his qualifications and committee assignments.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
Shareholders voted at the Annual Meeting to elect Ann M. Danner, William A. Lamkin, and Matthew P. Jordan to Class I of the Board for three-year terms, and ratified Deloitte & Touche LLP as the independent auditors for 2026, with specific vote tallies reported for each matter.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear disclosure of shareholder vote results from Virtu Financial's 2026 annual meeting held on June 10, 2026. The filing reports voting outcomes on three matters: election of Class II directors (Aaron Simons, Joseph J. Grano Jr., and Joanne M. Minieri), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. All three items passed with substantial majorities, making this a routine but material governance disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-10
Item 5.02
The Board elected Elena B. Poptodorova as an Independent Trustee on June 9, 2026, increasing the Board size from seven to eight members and assigning her to the Audit, Compensation, and Nominating and Governance committees.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
The Company's annual meeting of shareholders held on June 9, 2026 resulted in election of seven Trustees, approval of a non-binding advisory vote on named executive officer compensation, determination of frequency for future compensation advisory votes, and ratification of Deloitte & Touche LLP as independent auditors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Clean Energy Fuels' 2026 annual meeting held on June 10, 2026. The filing reports voting outcomes on three proposals: election of six directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
Astrana Health held its Annual Meeting on June 10, 2026, with shareholders voting on four proposals: election of nine directors, ratification of Ernst & Young LLP as independent auditor, advisory approval of executive compensation, and approval of the amended 2024 equity incentive plan. The filing discloses detailed vote tallies for all proposals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-10
Item 5.07
Argan Inc. held its 2026 Annual Meeting of Shareholders on June 10, 2026, with voting results on three matters: election of nine board members, non-binding say-on-pay approval, and ratification of Grant Thornton LLP as independent auditors.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-10
Item 8.01
Humacyte disclosed presentation of Phase 3 clinical trial results (V012) for its ATEV product in arteriovenous access for hemodialysis patients on June 10, 2026. While this is a significant clinical milestone for a medical device company, the disclosure does not fit neatly into the earnings_release category (which typically covers financial results) nor any other specific event type. The clinical trial readout is material to investors assessing the company's pipeline and regulatory prospects, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-10
Item 5.02
Shareholders approved and the Board adopted the 2026 Equity Incentive Plan, which amends the existing Omnibus Equity Incentive Plan and establishes the framework for future equity compensation grants to officers and directors, effective June 4, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
Perpetua Resources held its 2026 Annual General Meeting of Shareholders on June 4, 2026, with all four proposals passing by substantial majorities: fixing the board at nine directors, electing nine directors (including Marcelo Kim, Christopher J. Robison, and Alexander Sternhell), approving the 2026 Equity Incentive Plan, and ratifying PricewaterhouseCoopers LLP as auditor.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-10
Item 8.01
The Company disclosed two material litigation matters: a putative securities class action (Barnes et al. v. Perpetua Resources Corp.) where the court granted a motion to dismiss the amended complaint without prejudice, allowing a second amended complaint by July 3, 2026; and an environmental lawsuit relating to the Stibnite Gold Project where the court denied plaintiffs' preliminary injunction motion on May 29, 2026, with cross-motions for summary judgment and oral argument scheduled for June 24, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
Iovance held its Annual Meeting of Stockholders on June 10, 2026, with certified voting results on seven proposals including director elections, executive compensation advisory votes, auditor ratification, equity plan amendments, and a certificate of incorporation amendment to increase authorized shares. All proposals passed.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-10
Item 8.01
Iovance received marketing authorization from Australia's Therapeutic Goods Administration for Amtagvi® in advanced melanoma on June 4, 2026. This regulatory approval is material to the company's commercial prospects and pipeline.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-10
Item 1.01
Swarmer entered into a Common Stock Purchase Agreement with Lucid Capital Markets on June 10, 2026, granting Lucid the right to purchase up to 3,000,000 shares of common stock at 98% of VWAP over a 24-month period. This is a classic at-the-market (ATM) or equity line of credit arrangement that creates significant dilution risk. The filing explicitly states the shares are offered in reliance on Section 4(a)(2) (private placement exemption), and the Company expects to use proceeds for operations and expansion. This is a material dilutive issuance typical of small-cap companies raising capital through equity lines.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of McEwen Inc.'s annual shareholder meeting held June 4, 2026. The filing presents voting tallies for three proposals: (i) election of eleven directors, (ii) ratification of Ernst & Young LLP as independent auditor, and (iii) approval of common stock issuance to Robert R. McEwen. All three proposals passed with substantial majorities, making this a material governance event that investors rely on to assess board composition and auditor continuity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on six proposals: election of five directors (Dr. Khalid Islam, Chris A. Rallis, Marco Brughera, Jodi Cook, Jeffrey Hackman), appointment of auditors (Haskell & White LLP), advisory votes on executive compensation and frequency thereof, amendments to the 2020 Equity Incentive Plan, and adoption of the 2026 Equity Inducement Plan. All proposals were approved by shareholders on June 10, 2026. This is material as it confirms governance and compensation decisions affecting the company's leadership and capital structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-10
Item 2.01
Factorial Energy Inc. completed a business combination with CGC, a special purpose acquisition company. The transaction involved entry into material definitive agreements (amended and restated registration rights agreement, warrant agreement, indemnification agreements, and equity incentive plans) and resulted in a change of control, with CGC domesticating as a Delaware corporation, changing its name to Factorial Energy Inc., and ceasing to be a shell company. The combined entity's Series A Common Stock and Public Warrants commenced trading on Nasdaq under ticker symbols FAC and FACWW.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-10
Item 3.02
Factorial Energy Inc. completed an unregistered sale of equity securities under Section 4(a)(2) of the Securities Act in connection with the business combination, resulting in significant share dilution with registration rights granted for 80.6 million shares representing 88.1% of outstanding shares.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-10
Item 5.02
Seven directors (Siyu Huang, Alex Yu, Joseph Taylor, Uwe Keller, Liad Meidar, Dieter Zetsche, and Jon Nelson) were appointed to the PubCo Board, and four named executive officers were appointed effective immediately following the merger: Siyu Huang as CEO, Richard Wei as CFO, Alex Yu as CTO, and Jason Duva as General Counsel and Secretary.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-10
Item 4.01
CBIZ was dismissed as the registrant's independent auditor on June 5, 2026, and RSM US LLP was engaged as the new auditor on the same date. The filing states there were no disagreements or reportable events between the registrant and CBIZ.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-10
Item 5.03
In connection with the business combination closing, the registrant adopted amended articles of incorporation and bylaws, including lock-up provisions affecting share transferability and governance changes, and adopted a new Code of Business Conduct and Ethics.
View raw filing on EDGAR →